The Medical Letter - 2025
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
January 6, 2025 (Issue 1719)
- Drugs for Age-Related Macular Degeneration Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
- Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia The FDA has approved pilocarpine 0.4% preservativefree ophthalmic solution (Qlosi – Orasis) for treatment of presbyopia in adults. Pilocarpine 1.25% ophthalmic solution (Vuity) was approved in 2021 for the...
- Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease Vyalev (Abbvie), a solution for continuous subcutaneous infusion containing the prodrugs foscarbidopa and foslevodopa, has been approved by the FDA for treatment of motor fluctuations in adults...
- Revumenib (Revuforj) for Acute Leukemia (online only) Revumenib (Revuforj – Syndax), an oral menin inhibitor, has been approved by the FDA for treatment of relapsed or refractory acute leukemia in patients ≥1 year old with a lysine methyltransferase 2A...